YUHSpace

BROWSE

YUHSpace

Browsing by Yonsei Author : Sohn, Joo Hyuk

eperson profile image
Name :
Sohn, Joo Hyuk [손주혁]
orcid http://orcid.org/0000-0002-2303-2764
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (15045889800)

교수 기본정보

세부 전공
종양내과
이메일
oncosohn@yuhs.ac

실험실 기본정보

이름
유방암중개연구센터
위치
ABMRC 614호
구분
Wet Lab (100%), Dry Lab ( %)

연구소개

연구 내용
유방암의 중개연구 및 암환자 혈액내 DNA를 시퀀싱해서 얻은 전장유전체의 분석 연구

학생 참여 정보

학생들이 참여하면 좋을 연구
  • 연구에 대해 지도하면서 학생의 관심 분야를 의논한 후 결정하도록 하겠습니다.
학생 참여 시 사용하게 되는 장비 및 프로그램
  • 참여 결정되면 결정될 것입니다.

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 211

This table browses all dspace content
Issue DateTitleJournal Title
2026Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast Cancer JOURNAL OF BREAST CANCER
2026Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-marketing Surveillance Study in South Korea CANCER RESEARCH AND TREATMENT
2026Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer GENOME BIOLOGY
2026Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia ESMO OPEN
2026A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer ESMO OPEN
2026ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer NATURE COMMUNICATIONS
2026Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02ANNALS OF ONCOLOGY
2026Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy ANNALS OF ONCOLOGY
2026Overall survival with abemaciclib in early breast cancer ANNALS OF ONCOLOGY
2026Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study BREAST CANCER RESEARCH
2026OPERA-01: a phase III study of palazestrant for ER+, HER2-advanced breast cancer after CDK4/6 inhibitor therapy FUTURE ONCOLOGY
2025Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2025Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast CancerCLINICAL CANCER RESEARCH
2025Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21) ESMO OPEN
2025GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumoursBRITISH JOURNAL OF CANCER
2025Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21) BMC CANCER
2025Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trialNATURE MEDICINE
2025Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10) LANCET REGIONAL HEALTH-WESTERN PACIFIC
2025Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).Journal of Clinical Oncology
2025Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial ESMO OPEN
2025Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC ONCOLOGIST
2025Imlunestrant with or without Abemaciclib in Advanced Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2025Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study BREAST CANCER RESEARCH
2025Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 studyLANCET ONCOLOGY
2025A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial ANNALS OF ONCOLOGY
2025Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
2024Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial NATURE MEDICINE
2024Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study JOURNAL OF CLINICAL ONCOLOGY
2024Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2024A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer FUTURE ONCOLOGY
2024Reply to A. Okeya et alJOURNAL OF CLINICAL ONCOLOGY
2024Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study ESMO OPEN
2024Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialLANCET ONCOLOGY
2024Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study BREAST CANCER
2024Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3 ANNALS OF ONCOLOGY
2024A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer NPJ BREAST CANCER
2024Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer CANCER IMMUNOLOGY IMMUNOTHERAPY
2024Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer ISCIENCE
2024Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.Journal of Clinical Oncology
2024Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2-metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.JOURNAL OF CLINICAL ONCOLOGY
2024A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trialJOURNAL OF CLINICAL ONCOLOGY
2024Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study JOURNAL OF CLINICAL ONCOLOGY
2024Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancerJournal of Clinical Oncology
2024A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).Journal of Clinical Oncology
2024IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy CELL REPORTS MEDICINE
2024Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY BREAST CANCER RESEARCH AND TREATMENT
2024Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation EXPERIMENTAL AND MOLECULAR MEDICINE
2024Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) ANNALS OF ONCOLOGY
2024TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancerFUTURE ONCOLOGY
2024Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer CLINICAL CANCER RESEARCH
12345
  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links